Drug Profile


Alternative Names: AMG-479

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Amgen
  • Developer Amgen; Millennium; NantWorks; National Cancer Institute (USA); Novartis; Takeda; Takeda Oncology; UCLAs Jonsson Comprehensive Cancer Center
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Insulin-like growth factor-I receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ewing's sarcoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Ewing's sarcoma
  • Phase II Solid tumours
  • Phase Unknown Rhabdomyosarcoma
  • No development reported Breast cancer; Colorectal cancer; Sarcoma; Small cell lung cancer
  • Discontinued Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 01 Jun 2017 NantCell completes a phase I/II trial for Solid tumours (Combination therapy, Late-stage disease) in USA, Belgium, Canada and Spain (IV) (NCT01708161)
  • 10 Apr 2017 Ganitumab receives Orphan Drug status for Ewing's Sarcoma in USA
  • 10 Feb 2017 National Cancer Institute plans a phase I/II trial for Rhabdomyosarcoma in USA (NCT03041701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top